
Opinion|Videos|January 5, 2026
Shared Decision-Making Strategies with TYK2 Inhibition and Future Direction in Psoriasis Care
Panelists discuss the questions below in this video. Looking ahead, what are your hopes for the future of psoriasis care with targeted oral therapies like TYK2 inhibitors, and what final reflections do you have on their emerging role in clinical practice?
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
Looking ahead, what are your hopes for the future of psoriasis care with targeted oral therapies like TYK2 inhibitors, and what final reflections do you have on their emerging role in clinical practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5



























































